Recruiting
BIO|STREAM.CSP Study
NCT07393009· Biotronik SE & Co. KG· Source
Contact: Johannes Pfaffenberger
Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
NCT07298473· Medtronic Cardiac Ablation Solutions· Source
Contact: Tobias Reichlin
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265· Phase 2· Eisai Inc.· Source
Active, not recruiting
WATCHMAN FLX Pro European Registry
NCT07262255· Boston Scientific Corporation· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725· Phase 3· Azafaros B.V.· Source
Contact: Sandrina Schneider
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515· Phase 3· Azafaros B.V.· Source
Contact: Sandrina Schneider
Recruiting
Effect of Cognitively Challenging Physical Activity on Executive Functions in Pediatric Cancer Patients
NCT06839794· University of Bern· Source
Contact: Eva Brack, PD Dr. Dr.
Active, not recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798· The Leeds Teaching Hospitals NHS Trust· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· Phase 3· Kite, A Gilead Company· Source
Active, not recruiting
Affera Global Registry
NCT06026345· Medtronic Cardiac Ablation Solutions· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917· Inari Medical· Source
Contact: Marc Schindewolf, Dr. med.
Recruiting
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
NCT06146738· Jasper Gerritsen· Source
Contact: Philippe Schucht, MD PhD
Recruiting
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
NCT06146725· Jasper Gerritsen· Source
Contact: Philippe Schucht, MD PhD
Recruiting
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
NCT06283927· Jasper Gerritsen· Source
Contact: Philippe Schucht, MD PhD
Recruiting
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
NCT06273176· Erasmus Medical Center· Source
Contact: Philippe Schucht, MD PhD
Active, not recruiting
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280· Phase 1/2· Immunophotonics, Inc.· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries
NCT04971772· Cardionovum GmbH· Source
Active, not recruiting
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755· Medtronic Cardiovascular· Source
Recruiting
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
NCT06118723· Jasper Gerritsen· Source
Contact: Philippe Schucht, MD PhD
Active, not recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
NCT04798261· Penumbra Inc.· Source
Contact: Joanne Krasnoff
Active, not recruiting
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250· Medtronic Cardiovascular· Source
Active, not recruiting
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source
Active, not recruiting
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
NCT04150887· Phase 1· OncoVerity, Inc.· Source
Active, not recruiting
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
NCT04023526· Phase 2· OncoVerity, Inc.· Source
Active, not recruiting
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
NCT03049189· Phase 3· ITM Solucin GmbH· Source
Active, not recruiting
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661· Phase 2/3· Geron Corporation· Source
Active, not recruiting
PERIGON Pivotal Trial
NCT02088554· Medtronic Cardiac Surgery· Source
Recruiting
Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation
NCT07852221· Insel Gruppe AG, University Hospital Bern· Source
Contact: Nikola A Kozhuharov, PD Dr. med.